Precipio (PRPO) Projected to Announce Quarterly Earnings on Tuesday

Precipio (NASDAQ:PRPO) is anticipated to post its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Precipio to announce earnings of ($2.00) per share and revenue of $1.68 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 5:00 PM ET.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($2.00) by $1.88. Precipio had a negative net margin of 4.47% and a negative return on equity of 8.49%. The business had revenue of $7.02 million during the quarter, compared to analysts’ expectations of $1.68 million.

Precipio Stock Up 4.7%

Precipio stock traded up $0.84 during trading hours on Tuesday, hitting $18.63. The company had a trading volume of 7,592 shares, compared to its average volume of 58,235. The firm has a market capitalization of $33.35 million, a P/E ratio of -28.73 and a beta of 1.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.77 and a quick ratio of 1.56. The firm’s fifty day moving average is $24.33 and its 200-day moving average is $24.90. Precipio has a fifty-two week low of $17.79 and a fifty-two week high of $33.63.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About Precipio

Precipio, Inc (NASDAQ: PRPO) is a biotechnology and medical diagnostics company focused on improving the diagnosis of cancer and other complex diseases. The company combines specialized pathology expertise with laboratory testing and diagnostic technologies intended to help physicians identify disease accurately and support treatment decisions.

Precipio provides clinical laboratory services in areas including hematopathology, cytogenetics and molecular diagnostics. Its work is particularly focused on blood cancers and other hematologic disorders, where accurate classification can be challenging.